Roche hands cancer compound back to Repare after paying out $179M

2024-02-13

临床1期临床2期引进/卖出蛋白降解靶向嵌合体

Repare Therapeutics said Tuesday it regained full worldwide rights to camonsertib (RP-3500) from Roche, effective May 7. The deal termination, which comes just weeks after a milestone payment, was triggered by a review of the pharma’s pipeline and unnamed “external factors.” The news shaved about 16% off Repare’s share price Tuesday.

The precision oncology company, which uses a synthetic lethality approach to develop cancer therapeutics, last month scored a $40-million milestone payment after Roche dosed the first patient with camonsertib in the Phase II TAPISTRY trial. The study is enrolling patients with solid tumours to receive one of 11 different therapies based on their specific oncogenic genomic alterations. According to ClincalTrials.gov, patients are eligible to receive camonsertib if their cancer exhibits a SETD2 or ATM loss of function mutation.

Roche had gained rights to camonsertib in a 2022 deal that saw it shell out $125 million upfront. Along with the TAPISTRY payment, Repare had received another $13.6 million in milestones; the company had been eligible for up to $1.2 billion in total.

Clinical combos for cancer

In addition to TAPISTRY, the oral ATR inhibitor is being tested in one other trial sponsored by Roche, and at least two separate studies from Repare.

“We have been continuously running clinical trials for camonsertib since July 2020 and are excited to steward the progress of this promising therapy,” CEO Lloyd Segal said in a statement. “While we are disappointed to end this collaboration, we appreciate the contributions Roche has made to the programme.”

Roche is running the Phase I/II MORPHEUS trial in patients with metastatic non-small-cell lung cancer, which is testing camonsertib in combination with PD-L1 inhibitor Tecentriq (atezolizumab) and anti-VEGF antibody Avastin (bevacizumab).

Repare’s Phase 1 MYTHIC trial is evaluating camonsertib in combination with another programme in its pipeline: lunresertib, an oral small molecule inhibitor of PKMYT1. The trial is enrolling patients with advanced, recurrent tumours with detected CCNE1 amplification, or deleterious alterations in FBXW7 and other STEP2 genes.